You are here:
Two key factors set the Vaccine Alliance apart from other actors in the field of international health aid:
In this section, we explain Gavi’s unique business model and the six ways it delivers "added value".
Donor and developing countries need to see proof of the value of new vaccines before investing.
Immunisation is a commitment for life that requires guaranteed, long-term funding.
Developing countries decide for themselves how best to use Gavi support for immunisation.
It's not enough to buy new vaccines. They have to safely reach every child.
Gavi’s market shaping efforts aim to make life-saving vaccines and other immunisation products more accessible and affordable for lower-income countries.
National immunisation programes must survive long after Gavi support stops.
The Vaccine Alliance has helped strengthen health systems and immunisation services in more than 60 countries and increased injection safety.
20 January 2016
Ebola: $5m vaccine deal announced
02 December 2015
Measles Outbreaks Are a Sign of Bigger Problems
29 October 2015
World Health Organisation right to be wary about first malaria vaccine
06 October 2015
Make vaccine coverage a key UN health indicator
22 August 2015
Vaccinations Bring Hope, Bracelets Deliver Reminders
The New York Times
03 March 2015
Ebola vaccine research in Africa
02 October 2013
Laos becomes first South East Asian nation to introduce pneumococcal vaccine
04 May 2013
Sojo Stories: Immunizing 250 Million Children By 2015
27 March 2013
Seth Berkley on Immunization in Pakistan
Heartfile eForum Blog
05 October 2012
GAVI Alliance CEO: Leadership Is About Vision and Responsibility, Not Power
Concerned about the misuse of Gavi resources? Report it now.
© Gavi 2016
modal window here